12:29 | Lima, Jan. 27.
The information was revealed after unblinding the volunteer s participation in the clinical trial.
This measure was adopted following close consultation with the security and surveillance team, and after notifying the event to the National Health Institute (INS) in its capacity as regulatory authority which immediately supervised the events.
The data on the research product received by the participant was unblinded based on the recommendation of the regulatory authority and under the authorization of the Data Safety and Monitoring Committee.
The information revealed that the deceased participant was in the placebo group.
The UPCH worked in coordination with the study s security and surveillance team, as well as with regulatory authorities, in order to establish the sequence of events that led to the participant s unfortunate death.
2 Min Read
LIMA (Reuters) - A volunteer in the local Peruvian trial of a coronavirus vaccine produced by China’s Sinopharm Group Co Ltd has died from COVID-19-related pneumonia, the university carrying out the trial said on Tuesday.
Slideshow ( 2 images )
Cayetano Heredia University, which is involved with the study, said on the instructions of the Peruvian health regulator it had unblinded the volunteer’s participation in the trial and determined she had received the placebo rather than the vaccine.
“It is important to stipulate that the death of the participant is not related to the vaccine since she received the placebo, and we will therefore report to the relevant regulatory and ethics bodies and maintain the course of this phase three study,” the university said in a statement.
13:31 | Lima, Jan. 6. The President of the Republic Francisco Sagasti on Wednesday announced that the purchase of the first batch of vaccines against coronavirus (COVID-19) from the Chinese laboratory Sinopharm has been completed, adding that the first shipment will arrive this January. After long, complex, and tough negotiations that seemed frustrating at times, I can announce that we have completed the purchase of the first batch of the long-awaited vaccines against the pandemic, he said in a televised address to the nation from the Government Palace.
Sinopharm
purchase agreement for 38 million doses, the Head of State reported that a purchase agreement and commitment letter have been signed to receive a first shipment (one million doses) this January.
President Xi has pledged to make the country s vaccines a global public good
China s vaccine candidates are being considered by many developing countries
China approved its first Covid-19 vaccine for general public use, developed by state-owned drug maker Sinopharm.
The pharmaceutical giant announced on Thursday that the vaccine, which is said to be 79 per cent effective, had been approved.
ADVERTISEMENT
The efficacy rate is based on interim analysis of Phase III clinical trials of the drug, developed by the Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG).
In this photo taken on December 25, 2020, a staff member inspects syringes of COVID-19 inactivated vaccine products at a packaging plant of the Beijing Biological Products Institute
Pakistan set to buy China’s Sinopharm vaccine: Here s all you need to know
By
Thursday Dec 31, 2020
A volunteer gets checked before receiving a COVID-19 vaccine produced by China s Sinopharm during its trial at the Clinical Studies Center of Cayetano Heredia University in Lima on December 9, 2020. Photo: AFP
Pakistan will be purchasing 1.2 million doses of coronavirus vaccine from Chinese company Sinopharm early next year.
Sinopharm announced on December 30 that phase three trials of the vaccine showed it was 79% effective.
Sinopharm’s vaccines have been undergoing clinical trials in 10 countries, including Argentina and Morocco.
Pakistan will be purchasing 1.2 million doses of a coronavirus vaccine from China’s Sinopharm early next year, announced Federal Minister for Science and Technology Fawad Chaudhry earlier today.